# Kymera Therapeutics

Source: https://onco.cc/companies/kymera/  
OnCo record `kymera` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Oral degrader company, mostly immunology, whose CDK2 molecular-glue degrader was optioned by Gilead in 2026 for CCNE1-driven cancers.

## Summary

Kymera Therapeutics, based in Watertown, Massachusetts, and listed as KYMR, is an oral protein degrader company focused mostly on immunology, whose CDK2 molecular-glue degrader was optioned by Gilead in 2026 for CCNE1-driven cancers. Gilead paid 40 million dollars for an option in June 2025 and exercised it for 45 million dollars in April 2026 on the preclinical CDK2 glue degrader KT-200, aimed at CCNE1-amplified tumours and resistance to CDK4/6 inhibitors, while Kymera's own clinical pipeline against IRAK4, STAT6 and TYK2 is immunological. OnCo links it to ovarian and HR-positive breast cancer, to PROTACs and molecular glues and glue discovery platforms, to CDK4/6 as a target, to Gilead, and to ideas including glues that break the MYC-MAX partnership. The undruggable drivers are the bottleneck it bears on. Whether CDK2 degradation is tolerable is the open question.

## Fields

- Kind: Company
- Last checked: 2026-09-04
- HQ: Watertown, MA
- Type: biotech
- Website: https://www.kymeratx.com
- Ticker: KYMR

## Sources

- Gilead option exercise: https://www.fiercebiotech.com/biotech/gilead-pays-kymera-45m-glue-preclinical-protein-degrader-burgeoning-oncology-pipeline

## Connected records

- collections: [Fierce Biotech](https://onco.cc/collections/src-fierce-biotech/)
- cancers: [HR-positive / HER2-negative breast cancer](https://onco.cc/cancers/breast-hr-positive/), [Ovarian cancer](https://onco.cc/cancers/ovarian/)
- fronts: [Targeted Therapy](https://onco.cc/fronts/targeted-therapy/)
- technologies: [Molecular glue discovery platforms](https://onco.cc/technologies/molecular-glue-platforms/), [PROTACs & molecular glues (targeted protein degradation)](https://onco.cc/technologies/protac-degrader/)
- targets: [CDK4/6](https://onco.cc/targets/cdk4-6/)
- companies: [Gilead Sciences (incl. Kite)](https://onco.cc/companies/gilead/)
- bottlenecks: [The undruggable drivers](https://onco.cc/bottlenecks/b-undruggable-targets/)
- ideas: [An open degrader consortium against every undruggable driver transcription factor](https://onco.cc/ideas/idea-moon-open-degrader-consortium/), [Design protein degraders small enough to get into the brain](https://onco.cc/ideas/idea-bio2-brain-penetrant-glue-degraders/), [Find E3 ligases that only tumours have, and build degraders around them](https://onco.cc/ideas/idea-bio1-tumour-restricted-e3-atlas/), [Molecular glues that break the MYC-MAX partnership](https://onco.cc/ideas/idea-bio1-myc-max-molecular-glue/), [Screen glue-like compounds against every cancer cell line and publish it](https://onco.cc/ideas/idea-bio1-glue-degrader-atlas/), [Use antibodies to deliver protein-destroying drugs into the right cells](https://onco.cc/ideas/idea-bio1-antibody-degrader-conjugates/)

---
JSON: https://onco.cc/api/v1/entities/kymera.json